Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Earl

Showing results (241-250 of 265) with videos related to

Pageof 27
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2017
Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaksGustavo C Cerqueira, Ashlee M Earl, Christoph M Ernst, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
An Anaerobic Pathogen Rewires Host Metabolism to Fuel Oxidative Growth in the Inflamed GutLuisella Spiga, Ryan T Fansler, Alexandra Grote, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Plos Medicine|September 30, 2015
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-NatalKeira A Cohen, Thomas Abeel, Abigail Manson McGuire, et al.
Nature Communications|May 11, 2016
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Genome Medicine|April 5, 2022
Inter-species geographic signatures for tracing horizontal gene transfer and long-term persistence of carbapenem resistanceRauf Salamzade, Abigail L Manson, Bruce J Walker, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Physical Review Letters|November 1, 2000
Tau neutrinos favored over sterile neutrinos in atmospheric muon neutrino oscillationsS Fukuda, Y Fukuda, M Ishitsuka, et al.
Pageof 27

Showing results (241-250 of 265) with videos related to

Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2017
Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaksGustavo C Cerqueira, Ashlee M Earl, Christoph M Ernst, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
An Anaerobic Pathogen Rewires Host Metabolism to Fuel Oxidative Growth in the Inflamed GutLuisella Spiga, Ryan T Fansler, Alexandra Grote, et al.
The Lancet. Oncology|May 9, 2017
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Helen C Howard, et al.
Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.
British Journal of Cancer|October 11, 2012
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trialsH M Earl, L Hiller, J A Dunn, et al.
Plos Medicine|September 30, 2015
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-NatalKeira A Cohen, Thomas Abeel, Abigail Manson McGuire, et al.
Nature Communications|May 11, 2016
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapesBernard Pereira, Suet-Feung Chin, Oscar M Rueda, et al.
Genome Medicine|April 5, 2022
Inter-species geographic signatures for tracing horizontal gene transfer and long-term persistence of carbapenem resistanceRauf Salamzade, Abigail L Manson, Bruce J Walker, et al.
Nature|April 8, 2024
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancerJean E Abraham, Karen Pinilla, Alimu Dayimu, et al.
Physical Review Letters|November 1, 2000
Tau neutrinos favored over sterile neutrinos in atmospheric muon neutrino oscillationsS Fukuda, Y Fukuda, M Ishitsuka, et al.
Pageof 27